"As a cardiologist, I am excited about the prospect of this test. I understand its value to my patients and practice and I was happy to speak to my colleagues about its usefulness in the clinic," stated Dr. Simonini.
Aviir CEO Douglas Harrington , MD, said Aviir anticipates that the MIRISK VP test will become an important and widely used tool for physicians who want to provide their patients with a clearer picture of their individual heart health by providing critical information to high risk patients who may be incorrectly identified as intermediate risk by standard diagnostic methods.
About the MIRISK VP™ Assessment
The Aviir MIRISK VP test was developed out of research performed at the Stanford University School of Medicine. Researchers identified seven key proteins associated with the biological processes underlying formation and rupture of vulnerable plaque, which is the number one cause of a heart attack. MIRISK VP was shown to effectively measure these proteins in a patient's blood up to 5 years prior to an ensuing heart attack or unstable angina. Aviir's scientists developed sensitive multiplexed assays as well as a proprietary algorithm to detect those key proteins in an individual's blood and combines them with additional clinical risk factors to generate a more accurate 5-year risk score assessment for coronary heart disease (CHD). In an independent study, the MIRISK VP algorithm was shown to reclassify intermediate risk individuals as actually belonging either in a high or low risk group, significantly improving risk stratification (net reclassification index of 43%). By identifying patients who are actually at high risk, MIRISK VP assists physicians in developing effective treatment plans and implementing preventative measures to reduce the risk of a heart attack when they can be most beneficial. When used in conjunction with addi
|SOURCE Aviir Inc.|
Copyright©2012 PR Newswire.
All rights reserved